Elicio Q2 net loss $7.2M; Phase 1 data show 100% T cell response; Phase 2 enrollment Q4

Elicio Therapeutics, Inc.

2024-Q2 EPS reported -$1.77

Net loss of $7.2M ($0.64 per share) for Q2 2024; cash $3.4M at June 30, but subsequent financings raised ~$29.6M net.
AMPLIFY-7P Phase 1 data: 100% of patients developed mKRAS-specific T-cell response; median DFS not reached at RP2D (4.9mg).
Phase 2 randomized trial enrollment expected to complete Q4 2024; interim analysis anticipated Q1 2025.
AMPLIFY-201 long-term follow-up to be terminated; updated data at upcoming medical meetings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.